Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Objective: Ketamine may reduce suicidal ideation in treatment-resistant depression. But it is not known how quickly this occurs and how long it persists. We undertook a systematic review and meta-analysis to determine the short- and long-term effectiveness of ketamine for suicidality. Method: CENTRAL, EMBASE, Medline, and PsycINFO were searched until 12 December 2018. Randomised controlled trials of ketamine or esketamine reporting data on suicidal ideation, self-harm, attempted or completed suicide in adults diagnosed with any psychiatric disorder were included. Two reviewers independently extracted data, and certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation tool. Standardised mean difference was used for continuous outcomes. Results: Twenty-five reports from 15 independent trials, with a total of 572 participants diagnosed with predominately affective disorders, were included. The evidence was rated moderate to low. In most trials, ketamine was administered at 0.5 mg/kg via a single intravenous infusion over a 30- to 45-minute period. Only a single trial of intranasal esketamine was identified. At 4 hours post-infusion, treatment with ketamine was associated with a significant reduction in suicidal ideation scores (standardised mean difference = −0.51, 95% confidence interval = [−1.00, −0.03]), which persisted until 72 hours post-infusion (time points between 12 and 24 hours: standardised mean difference = −0.63, 95% confidence interval = [−0.99, −0.26]; between 24 and 72 hours: standardised mean difference = −0.57, 95% confidence interval = [−0.99, −0.14]), but not thereafter. However, there was marked heterogeneity of results. In a single trial of esketamine, marginal effects on suicidal ideation were observed. In terms of actual suicidal behaviour, there were virtually no data on effects of ketamine or esketamine. Conclusion: A single infusion of ketamine may have a short-term (up to 72 hours) beneficial impact on suicidal thoughts. While confirmation of these results in further trials is needed, they suggest possible use of ketamine to treat acute suicidality. Means of sustaining any anti-suicidal effect need to be found.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple meta-analyses and systematic reviews have demonstrated that ketamine significantly reduces suicidal ideation within one day and up to six weeks, an effect that appears to be at least partially independent of its effects on mood [72][73][74][75].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [74]
Experimental — accuracy not yet measuredIn the citing paper
“A meta-analysis12 showed a beneficial effect on suicidal ideation scores within 4 hours after infusion, lasting for at least the first 72 hours.”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Cochrane Database of Systematic Reviews
(2008) · Encyclopedia of Public Health · doi:10.1007/978-1-4020-5614-7_436 · Cited by 4,527
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 2×
“We also had to exclude some studies either because they did not report information on suicidality (e.g. Abdallah et al., 2012; Alizadeh et al., 2015; Berman et al., 2000; Daly et al., 2018; Feder et al., 2014; Gálvez et al., 2017; Lai et al., 2014; Lapidus et al., 2014; Li et al., 2016; OchsRoss et…”
ResultA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Suicide prevention strategies revisited: 10-year systematic review
Zalsman, G., Hawton, K., Wasserman, D., van Heeringen, K., Arensman, E., Sarchiapone, M., Carli, V., Höschl, C., Barzilay, R., Balazs, J., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30030-x · Cited by 1,765 · cited 3×
“Because of the increasing emphasis on finding effective interventions to reduce suicides (Zalsman et al., 2016), and the publication of new trials designed a priori to include patients with clinically significant levels of suicidal ideation and using specific suicidal ideation rating scales, we undertook a systematic…”
BackgroundMethodSelf-citationMalhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842 · cited 7×
“Australian & New Zealand Journal of Psychiatry, 54(1) Introduction Suicidal ideation and self-harm are frequent and potentially life-threatening major public health problems, especially for people with severe mental health issues and mood disorders (Malhi et al., 2015).”
BackgroundInfluentialDaly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718 · cited 3×
“…some studies either because they did not report information on suicidality (e.g. Abdallah et al., 2012; Alizadeh et al., 2015; Berman et al., 2000; Daly et al., 2018; Feder et al., 2014; Gálvez et al., 2017; Lai et al., 2014; Lapidus et al., 2014; Li et al., 2016; OchsRoss et al., 2019; Phillips…”
BackgroundMethodWilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696 · cited 7×
“In terms of mechanisms of the effect of ketamine on suicidality, the most obvious is through its impact on depression, although, as noted above, the two may not be completely correlated (Wilkinson et al., 2018), and the treatment effect for depression appears to last longer than that for suicidality (Caddy et al.”
BackgroundResultSelf-citationFeder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., Kirkwood, K., aan het Rot, M., Lapidus, K. A. B., Wan, L.-B., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.62 · Cited by 613 · cited 1×
“…because they did not report information on suicidality (e.g. Abdallah et al., 2012; Alizadeh et al., 2015; Berman et al., 2000; Daly et al., 2018; Feder et al., 2014; Gálvez et al., 2017; Lai et al., 2014; Lapidus et al., 2014; Li et al., 2016; OchsRoss et al., 2019; Phillips et al., 2017;…”
BackgroundSelf-citationCarroll, R., Metcalfe, C., & Gunnell, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089944 · Cited by 586 · cited 2×
“People presenting to hospital services for self-harm have a considerable risk of new episodes of self-harm (an average of 16.3% within a year in one review [Carroll et al., 2014], but well over 20% in other recent studies [Geulayov et al., 2016]) and also of completed suicide (1.6”
BackgroundInfluential
Research works printed but not linked: 3
- Hawton K, 2016, Cochrane Database of Systematic Reviews, 5
- McCloud T, 2015, Cochrane Database of Systematic Reviews, 9
- Sos P, 2013, Neuroendocrinology Letters, 34, 287
Cited by
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
“The reduction in suicidal ideation has been reported to endure for up to 7 days from the previous administration (73).”
BackgroundSelf-citationBahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408
Knipe, D., Padmanathan, P., Newton-Howes, G., Chan, L. F., & Kapur, N. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00173-8 · Cited by 331
Walsh, Z., Mollaahmetoglu, O. M., Rootman, J., Golsof, S., Keeler, J., Marsh, B., Nutt, D. J., & Morgan, C. J. A. (2022) · BJPsych Open · doi:10.1192/bjo.2021.1061 · Cited by 186
Abbar, M., Demattei, C., El-Hage, W., Llorca, P.-M., Samalin, L., Demaricourt, P., Gaillard, R., Courtet, P., Vaiva, G., Gorwood, P., et al. (2022) · BMJ · doi:10.1136/bmj-2021-067194 · Cited by 181
Metadata
- Authors
- Witt, K., Potts, J., Hubers, A., Grunebaum, M. F., Murrough, J. W., Loo, C., Cipriani, A., & Hawton, K.
- Affiliations
- University of Oxford (GB)
- Oxford Health NHS Foundation Trust (GB)
- Leiden University Medical Center (NL)
- Columbia University Irving Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
- Black Dog Institute (AU)
- Corresponding author
- Hawton, Keith
- ORCID
- Venue
- Australian & New Zealand Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2019-11-15
- Volume
- 54
- Issue
- 1
- Pages
- 29-45
- ISSN
- 0004-8674 (ISSN-L)
- 1440-1614
- OpenAlex
- W2979686202
- Cited by
- 202
- References
- 51
- Citations by year
- 2026: 12 · 2025: 24 · 2024: 31 · 2023: 38 · 2022: 47 · 2021: 30 · 2020: 19 · 2019: 1
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-05-14)
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc-nd
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Australian & New Zealand Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- Funders
- national institute for health research (Oxford Health Biomedical Research Centre (BRC-1215)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- ketamine, esketamine, suicidal ideation, suicidality, treatment-resistant depression, mental illness, intravenous infusion, intranasal administration, self-harm, suicide prevention, short-term effectiveness
- MeSH terms
- Antidepressive Agents, Humans, Ketamine, Suicidal Ideation, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. https://app.cochat.ai/papers/10.1177/0004867419883341
- The paper
- Witt, K., Potts, J., Hubers, A., Grunebaum, M. F., Murrough, J. W., Loo, C., Cipriani, A., & Hawton, K. (2020). Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.1177/0004867419883341
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.